Investors - Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Middle area:

Key facts & figures

Sanofi is a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.

  • 2012 net sales: €34,947 million, +4.7% on a reported basis, +0.5% at constant exchange rates (CER) versus 2011
  • 2012 business EPS: €6.20, -6.8% on a reported basis, -12.8% at CER versus 2011
 

Growth Platforms

Sanofi has identified key growth platforms: Emerging Markets (World excluding U.S., Canada, Western Europe, Japan, Australia and New Zealand), Diabetes Solutions, Human Vaccines, Consumer Health Care, Animal Health, New Genzyme and Other Innovative Products.

  • 2012 consolidated net sales of growth platforms: €23,548 million, +9.9% at CER, +7.8% with Genzyme pro forma
  • Growth platforms represent 67.4% of total consolidated sales in 2012 compared with 61.7% in 2011
Growth platforms
€ million2012 net salesChange at CER
Emerging Markets*11,145+8.3%
Emerging Markets
excluding Diabetes, Vaccines, CHC, Animal Health,
New Genzyme and Other Innovative Products
6,286+0.5%
Diabetes5,782+16.7%
Vaccines3,897+5.7%
Consumer Health Care3,008+9.9%
Animal Health2,179+3.1%
New Genzyme1,785+16.9%**
Other Innovative Products***611+10.5%
Total Growth Platforms23,548+9.9%
Total Growth Platforms with Genzyme pro forma23,548+7.8%

* Include Diabetes, Vaccines, Consumer Health Care, Animal Health, New Genzyme and Other Innovative Products sales generated in Emerging Market. 
** On a constant structure basis and at constant exchange rates.
*** Includes recent product launches which do not belong to the other Growth Platforms listed above: Multaq®, Jevtana®, Zaltrap®, and Mozobil® pro forma.

 

Pharmaceuticals

  • 2012 net sales of the pharmaceuticals business: €28,871 million, -0.4% at CER

Sanofi's pharmaceuticals business notably focuses on diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields.

It also includes Consumer Health Care, one of our important growth platforms.

  • 2012 net sales of Consumer Health Care: €3,008 million, +9.9% at CER

In addition, our pharmaceuticals portfolio comprises Generics.

  • 2012 net sales of Generics: €1,844 million, +5.0% at CER
 

Human Vaccines

Sanofi Pasteur, the fully integrated Vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 serious infectious diseases.

  • 2012 net sales of the Vaccines business: €3,897 million, + 5.7% at CER
  • Non-consolidated 2012 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €845 million, +6.8% on a reported basis
 

Animal Health

Our Animal Health activity is carried out through Merial, that is one of the world’s leading animal healthcare companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.

  • 2012 sales of Merial: €2,179 million, +3.1% at CER
 

Geographic Presence

Sanofi has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. 

Sanofi is the established leader in Emerging Markets, holding top positions in the main countries. In 2012, Emerging Markets totaled €11,145 million, an increase of 8.3%. Emerging Markets sales contribute to 31.9% of Group sales and are the most important contributors to the region sales.

 

Right area:

Stock Market

IAS19R

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013

 

Your services

Tools menu:

© Sanofi 2004-2013 - All rights reserved - Update: March 25, 2013

Site complies with W3C WCAG 2.0 (new window, in english)